Literature DB >> 27081863

The downregulation of miR‑125a‑5p functions as a tumor suppressor by directly targeting MMP‑11 in osteosarcoma.

Niyazi Waresijiang1, Jungang Sun1, Rewuti Abuduaini1, Tayier Jiang1, Wenzheng Zhou1, Hong Yuan1.   

Abstract

Osteosarcoma is one of the most common primary malignant bone cancers in juveniles and adults. Increasingly, reports indicate that microRNAs (miRNAs) may provide novel therapeutic targets for cancer treatment. The aim of the present study was to investigate the expression of miR‑125a‑5p and to identify its functional significance in osteosarcoma. This indicated that miR‑125a‑5p was downregulated in osteosarcoma tissue and cell lines using reverse transcription‑quantitative polymerase chain reaction. Following transfection with miR‑125a‑5p mimics or the negative control, cell migration, invasion and epithelial‑mesenchymal transition (EMT) assays were conducted in osteosarcoma cells. These results indicated that the overexpression of miR‑125a‑5p resulted in inhibited osteosarcoma cell migration, invasion and EMT in vitro. Furthermore, mechanistic studies showed that matrix metallopeptidase‑11 (MMP‑11), was a direct target of miR‑125a‑5p in osteosarcoma. Taken together, the data demonstrate that miR‑125a‑5p functions as a tumor suppressor gene and serves an important role in inhibiting osteosarcoma cell migration, invasion and EMT by targeting MMP‑11.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27081863     DOI: 10.3892/mmr.2016.5141

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  13 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

3.  MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88.

Authors:  Fan Zhang; Yanjie Zhu; Guoxin Fan; Shuo Hu
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

4.  MicroRNA-379 inhibits the proliferation, migration and invasion of human osteosarcoma cells by targetting EIF4G2.

Authors:  Xi Xie; Yu-Sheng Li; Wen-Feng Xiao; Zhen-Han Deng; Hong-Bo He; Qing Liu; Wei Luo
Journal:  Biosci Rep       Date:  2017-05-17       Impact factor: 3.840

5.  Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma.

Authors:  Qiao Zhang; Guo-Sheng Zhao; Ya Cao; Xue-Feng Tang; Qiu-Lin Tan; Lu Lin; Qiao-Nan Guo
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

6.  miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.

Authors:  Lijun Yu; Min Meng; Yun Bao; Chao Zhang; Bei Gao; Rina Sa; Wenyuan Luo
Journal:  Yonsei Med J       Date:  2019-09       Impact factor: 2.759

7.  Correlation between chemotherapy resistance in osteosarcoma patients and PAK5 and Ezrin gene expression.

Authors:  Qian Liu; Bo Xu; Wanshan Zhou
Journal:  Oncol Lett       Date:  2017-11-06       Impact factor: 2.967

8.  Inhibitory effect of icariin on osteosarcoma cell proliferation via the Wnt/β-catenin signaling pathway.

Authors:  Yuxin Ren; Fuqiang Zhu; Zhendong Liu
Journal:  Oncol Lett       Date:  2018-05-29       Impact factor: 2.967

9.  Identification of Novel Target for Osteosarcoma by Network Analysis.

Authors:  Li-Qiang Zhi; Yi-Xin Yang; Shu-Xin Yao; Zhong Qing; Jian-Bing Ma
Journal:  Med Sci Monit       Date:  2018-08-25

Review 10.  The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review.

Authors:  Argyris C Hadjimichael; Athanasios F Foukas; Olga D Savvidou; Andreas F Mavrogenis; Amanda K Psyrri; Panayiotis J Papagelopoulos
Journal:  Clin Sarcoma Res       Date:  2020-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.